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Targeted gold-coated iron oxide 
nanoparticles for CD163 detection 
in atherosclerosis by MRI
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CD163 is a membrane receptor expressed by macrophage lineage. Studies performed in 
atherosclerosis have shown that CD163 expression is increased at inflammatory sites, pointing at 
the presence of intraplaque hemorrhagic sites or asymptomatic plaques. Hence, imaging of CD163 
expressing macrophages is an interesting strategy in order to detect atherosclerotic plaques. We 
have prepared a targeted probe based on gold-coated iron oxide nanoparticles vectorized with 
an anti-CD163 antibody for the specific detection of CD163 by MRI. Firstly, the specificity of the 
targeted probe was validated in vitro by incubation of the probe with CD163(+) or (−) macrophages. 
The probe was able to selectively detect CD163(+) macrophages both in human and murine cells. 
Subsequently, the targeted probe was injected in 16 weeks old apoE deficient mice developing 
atherosclerotic lesions and the pararenal abdominal aorta was imaged by MRI. The accumulation 
of probe in the site of interest increased over time and the signal intensity decreased significantly 
48 hours after the injection. Hence, we have developed a highly sensitive targeted probe capable of 
detecting CD163-expressing macrophages that could provide useful information about the state of 
the atheromatous lesions.
Atherosclerosis is a complex disease that involves chronic inflammation and remodelling processes that 
may lead to the stenosis of the aorta. It can slowly progress over decades but under certain circumstances, 
it can either grow quickly or destabilize, leading to an ischemic event1. Its high morbidity and associ-
ated mortality have made atherothrombosis one of the leading causes of death in the developed world. 
Consequently, a large amount of resources are spent every year trying to improve its diagnosis, prognosis 
and treatment with the purpose of preventing a fatal event1,2.
CD163 is a membrane receptor which functions primarily as a hemoglobin (Hb) scavenger receptor, 
removing the complex hemoglobin-haptoglobin from the plasma and avoiding the toxic effects of free 
Hb. The role of CD163 has been widely studied and linked with inflammation through its function 
of removing pro-inflammatory ligands such as the TNF superfamily member, TWEAK3. It has been 
described that CD163 is expressed by the monocytic-macrophage lineage, although monocytes have a 
modest expression level that is increased when they acquire macrophage characteristics3. Macrophages 
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are one of the main inflammatory cells that play key role in the development and progression of atheroma 
plaque4. Studies performed in atherosclerosis have shown that CD163 is expressed by anti-inflammatory 
M2-macrophages instead of pro-inflammatory M1-macrophages and its expression is increased at 
inflammatory sites, specially in plaques at sites of hemorrhage5,6 or in asymptomatic plaques7 while 
healthy aortas do not contain or contain few CD163 (+ ) cells8,9.
Magnetic resonance imaging (MRI) has gained relevance in cardiovascular pathology detection 
because of its good spatial resolution and average contrast agent sensitivity10. The development of new 
contrast agents that provide more than an imaging enhancement is one of the main hot topics in MRI 
development nowadays. In the field of contrast enhanced imaging of atherosclerosis, the detection of 
the plaque presence is no longer enough and efforts have been focused on providing improved informa-
tion, in a non-invasive way, about the molecular composition and/or the state of the plaque. Targeting 
of macrophages (usually total population or M1 fraction) with T1 or T2 contrast agents is a frequent 
strategy for atherosclerosis imaging by magnetic resonance11, either by passive labelling12–14 or by active 
targeting of membrane receptors with vectorized probes15–20. Nano-sized superparamagnetic iron oxide 
probes have been previously explored as T2 contrast agents for atheroma plaque imaging12–15,21. Among 
them, gold-coated iron oxide nanoparticles (NP) are particularly stable and versatile platforms. The gold 
coating protects the magnetite core from oxidation and allows for easy and practical functionalization 
of the nanoparticle surface by using thiol-ending ligands22. Indeed, gold-coated iron oxide nanoparticles 
vectorized with antibodies have been successfully prepared and validated as contrast agents both in vitro 
and in vivo in the targeting of different types of cells23–25. Herein, we prepared gold-coated iron oxide 
nanoparticles functionalized with antibodies against CD163 as a T2 contrast agent for the detection of 
M2-macrophages. Such probe was able to selectively bind to CD163-expressing macrophages in vitro in 
human and murine cells, as well as in vivo in a murine model of atherosclerosis. We demonstrated the 
ability of our probe to detect CD163 in the pathological tissue, as well as its versatility to be vectorized 
with immunoglobulin-G type (IgG) antibodies of our election23–25.
Results
Characterization of nanoparticles. The prepared nanoparticles consisted of a gold-coated iron 
oxide core covered with thiol ligands bearing either a mannose or a carboxylic acid. ProtG was cova-
lently linked through a peptide bond to the carboxylic moieties and IgG antibodies subsequently grafted 
onto them (Fig.  1A). Bradford analysis of the unbound protG or antibody found in each step of the 
functionalization showed that the amount of protG-IgG complex on each nanoparticle ranged from 1 
to 2 units. Further evidence of the grafting of the antibodies on the nanoparticles was obtained by SDS-
PAGE gels of digested nanoparticles which showed the typical 2 bands of IgG antibodies, at 25 KDa and 
Figure 1. Characterization of glyconanoparticles. (A) Schematic representation of the nanoparticles.  
(B) UV-Vis spectra of all nanoparticles showing the appearance of the characteristic plasmon of gold. Due 
to their different solubilities, Fe3O4 NPs and Fe3O4@Au NPs were measured in hexane solution, whereas the 
rest were measured in water. (C) TEM micrograph and histogram of Fe3O4 NPs. (D) TEM micrograph and 
histogram of Fe3O4@Au NPs. (E) TEM micrograph and histogram of Fe3O4@Au@Man/CO2H NPs. (F) TEM 
micrograph and histogram of NP-CD163.
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50 KDa for the light and heavy chains, respectively (See supplemental Figure S4)23. TEM micrographs 
showed that the average diameter of iron oxide core was 3.2 nm, which increased up to 6.1 nm after 
the gold coating process (Fig. 1C–F). UV-Vis spectra were measured and as expected the characteristic 
plasmon resonance band of gold at around 520 nm appeared in all nanoparticles after the gold coating 
process (Fig. 1B). Gold and iron content was obtained by ICP-OES (Inductively coupled plasma - optical 
emission spectroscopy) analysis on Fe3O4@Au@Man/CO2H NPs and it was found to be 59.3 ± 0.8% and 
4.03 ± 0.05% in weight, respectively. Relaxivity measurements were performed at 11.7 T and room tem-
perature resulting in r2 and r1 values of 160 mM−1s−1 and 10 mM−1s−1, respectively. The full characteri-
zation of these nanoparticles, as superparamagnetic materials and contrast agents, has been previously 
described by our group22–26.
As part of the characterization of the NPs cell viability, toxicological profile, excretion and biodis-
tribution studies were performed using NP-CD163(m). Cytotoxicity was not detected on RAW264.7 
cell cultures incubated with increasing amounts of the tested probe (See supplemental Figure S5). In 
addition, the biochemical profiles of the control and the injected groups and were very similar. Urea 
and blood urea nitrogen levels were decreased at 24 hours after NP-CD163(m) injection, showing a 
better kidney function. Alkaline phosphatase activity (AP) was increased at 24 hours after injection 
but other metabolic liver enzymes and related metabolites such as bilirubin were similar to the control 
group. Also this increase of AP activity diminished to normal range at 48 hours post-injection (See 
supplemental Table S1). In addition, histopathological analysis was performed comparing tissue sections 
(stained with hematoxylin-eosin) between the control and injected groups no differences were observed 
(See supplemental Figure S6). Post-mortem gold content analysis of main organs by ICP-OES 48 hours 
after injection showed that NP-CD163(m) accumulated mainly in the liver (below 10% of the injected 
dose), followed in decreasing order by accumulation in spleen, lung and kidney (less than 0.5% of the 
injected dose for each tissue). At that time point, NPs were not detected neither in serum nor in urine 
by ICP-OES. Aorta of ApoE mice that have not developed atheroma plaques was also examined showing 
non-detectable accumulation of probe (See supplemental Figure S7). Gold deposits were detected by 
gold staining in tissue sections obtained from several organs, which was in agreement with the results 
obtained by ICP-OES (See supplemental Figure S8).
Binding of nanoparticles to CD163, in vitro models. The incubation of cells that expressed (+ ) 
or not (− ) CD163 (Fig.  2A,D) with the targeted or control probes showed that the NPs bearing the 
anti-CD163 antibody could selectively detect CD163 expressing macrophages (Fig. 2B-C, E-F). In both 
human and murine CD163 (+ ) cells incubated with NP-CD163, there was a significant decrease in the 
T2 values with respect to CD163 (− ) macrophages incubated with the same probe (p < 0.05 either THP-1 
or mouse peritoneal macrophages) (See Supplementary tables S1-S6 for statistical details). Likewise, T2 
values were significantly lower than those for the same cells incubated with the NP-IgG control probe 
compared with NP-CD163 (p < 0.001 in THP-1 cell line and p < 0.01 in mouse peritoneal macrophages). 
Incubation with increasing amounts of free antibody blocked the targeting of CD163 by the NP-CD163 
probe with a T2 values similar to that of cells not expressing CD163 or those that were incubated with 
control probe. This fact showed the specificity of the vectorized probe to target CD163 and excluded 
unspecific signal due to the probe.
In vivo CD163 detection in a murine model. ApoE− /− and wild type mice were both injected in 
separate experiments with either NP-CD163(m) or NP-IgG(m) and the pararenal abdominal aorta was 
imaged at four time points: before the injection and at 1, 24 and 48 hours post-injection. No differences 
were seen at 1hour post-injection (data not shown), but a signal decrease in the aortic wall was observed 
in apoE− /− mice injected with NP-CD163 (n = 9) over time with respect to the pre-injection signal. 
At 24 hours there was a signal decrease that became significant at 48 hours after the injection (p < 0.01). 
Conversely, when the same type of mice were injected with the control probe NP-IgG(m) there were not 
significant signal variations over time or in healthy mice (See Supplementary tables S7-S9 for statistical 
details). Likewise, the wall signal intensity did not vary compared to pre-injection signal in the case of 
wild type mice injected with either NP-CD163(m) or NP-IgG(m) (Fig. 3).
Finally, 4 of the apoE− /− mice that were injected with NP-CD163 were scanned in the MRI 6 days 
after the injection to study the clearance of the nanoparticles, and a recovery of the signal comparable to 
pre-injection signal intensity was observed (Figure S5 in supplemental material).
Immunohistochemistry validation. The histology of the apoE− /− aortas, harvested after MRI 
scan, showed that all the mice had atherosclerotic lesions in the MRI scanned area (Fig. 4) with an aver-
age size of 50,000 ± 14,000 μ m2. The plaques in the aortic wall were composed by a layer of smooth mus-
cle cells (Fig. 4A) with small lipid deposits (oil red staining, Fig. 4B) and with the presence of infiltrated 
macrophages (CD68, Fig. 4C). MRI results were confirmed in the atherosclerotic mice samples by CD163 
(Fig. 4D), and CD68 staining. The incubation with an isotype-matched immunoglobulin was used as a 
negative control, showing the specificity of the immunohistochemistry (Supplemental Figure S6).
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Discussion
Imaging macrophages in atherosclerosis is an appealing strategy since they play an important role in 
the development, growth and rupture of atherosclerotic plaque. In particular, the use of targeted probes 
specifically directed to the detection of subtypes of macrophages could provide useful information on the 
composition of the plaque. For these reasons, the use of a targeted probe detection of CD163-expressing 
macrophages in atherosclerosis by MRI could be of interest, because these types of macrophages, although 
not exclusively, are accumulated in hemorrhaged or asymptomatic plaques5,7.
Iron oxide nanoparticles are an alternative to gadolinium based contrast agents for patients with renal 
disorders due to nephrogenic systemic fibrosis that the gadolinium may induce27,28. Moreover, by coating 
those iron oxide nanoparticles with gold we achieved a very versatile platform due to the easy function-
alization of the NP surface by using thiol-ending ligands taking advantage of the stability of gold-sulphur 
bond. Hence, following an established procedure we were able to successfully prepare and characterize 
gold-coated iron oxide nanoparticles linked to anti-CD163 antibodies. Given their high specificity and 
availability against many proteins or their modifications, antibodies have been successfully used as vec-
tors for the targeting of many proteins, also in atherosclerosis29. The oriented grafting of IgG antibodies 
on the nanoparticles by the Fc leaving the Fab exposed for recognition was a challenge that was overcome 
by the use of protG. Such protein is known to bind to IgG antibodies in the desired oriented manner23. 
The amount of protG-antibody complex ranged from 1 to 2 units per nanoparticle, which is a desirable 
amount to ensure that a greater number of nanoparticles link to the receptors. This platform may also be 
able to link any other antibody binding proteins (A, L or recombinant A/G) allowing also the conjugation 
of non-IgG antibodies that would potentially enable us to vectorized the probe with any type of antibody.
Subsequently, the probe was tested in vitro by incubation of the targeted probe (NP-CD163) and 
the negative control probe (NP-IgG) with both CD163 (+ ) and (− ) macrophages. The same trend was 
observed in both human and mice cells and a significant decrease of the T2 values were observed when 
NP-CD163 was incubated with macrophages expressing CD163, whereas the T2 value did not decrease 
Figure 2. CD163 detection in in vitro models. (A) Western blot of CD163 expression and α -actin (loading 
control) in THP-1 macrophages cell lysates with or without dexamethasone treatment for 24 hours.  
(B) Graph showing the normalized T2 values obtained from MRI images of human macrophages CD163 (+ ) 
and CD163 (− ) incubated with NP-CD163(h) and NP-IgG(h), n  = 3. All the replicates were normalized 
to the blank (cells that have not been incubated with any nanoparticles). The error bars shows the SEM. 
$p < 0.05 versus Blank; *p < 0.05, **p < 0.01 and ***p < 0.001 versus NP-CD163(+ ) (C) Representative 
MRI phantoms of human macrophages CD163 (+ ) and CD163 (− ) incubated with NP-CD163(h) and NP-
IgG(h). (D) Immunodetection of CD163 expression in murine macrophages with or without dexamethasone 
treatment. Propidium iodide (PI) was used for nuclei staining. (E) Graph showing the normalized mean 
value obtained from MRI images of murine macrophages CD163 (+ ) and CD163 (− ) incubated with 
NP-CD163(m) and NP-IgG(m), n = 3. All the replicates were normalized to the blank (cells that have not 
been incubated with any nanoparticles). The error bars shows the SEM. $$p < 0.01 versus Blank; *p < 0.05 
and **p < 0.01 versus NP-CD163(+ ); #p < 0.05 versus Ab 1:1. (F) Representative MRI phantoms of murine 
macrophages CD163 (+) and CD163 (−) incubated with NP-CD163(m) and NP-IgG(m).
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in a significant manner when the same cells were incubated with the control probe NP-IgG. From these 
data we concluded that the probe specifically targeted macrophages that expressed CD163, but in order 
to prove that the specificity of the nanoparticle was due to CD163 receptor recognition we performed 
inhibition experiments incubating with increasing concentration of free antibody before probe target-
ing. The unlabelled antibody blocked the targeting of CD163 (+ ) macrophages with the NP-CD163 
probe both in human and in mice cells. It is noteworthy that one equivalent of free antibody was able 
to block completely the NP-CD163 T2 signal. This can be explained because the NP-CD163 probe is 
more steric hindered than the free antibody and/or the link of the antibody to the nanoparticle might 
decrease the affinity for its target. Additional control experiments were performed to exclude a potential 
mannose-directed binding of the NPs to macrophages. For this purpose NPs without ProtG and anti-
bodies were incubated with both CD163 (+ ) and (− ) cells and the binding analyzed by MRI. Those NPs 
bound abundantly and indiscriminately to both types of cells due to the presence of mannose receptors 
(data not shown), however, when the NPs were functionalized with IgG antibodies we only detected 
significant binding when NP-CD163 was incubated with CD163 (+ ) cells (Fig.  2B,E). To sum up, all 
these results demonstrated that the probe was accumulated by CD163 (+ ) macrophages only through 
their interaction with the antibody. Hence the selected probe was suitable for the selective detection of 
M2-macrophages with respect to pro-inflammatory M1-macrophages in both human and mice cells.
Once the specificity of the probe was tested in vitro, the targeted and control probes were injected in 
mice developing atherosclerotic lesions and wild type mice as healthy controls. As shown by the images, 
the accumulation of probe in the site of interest increased over time and became significant 48 hours 
after the injection in atherosclerotic mice. The fact that the probe is not accumulated in healthy aorta 
Figure 3. Plaque detection in apoE−/− mouse model. (A) Representative magnetic resonance images 
obtain before (0 h) and after (24 h, 48 h) the injection of each type of nanoparticles. The white arrows point 
at slightly darker areas with respect to the pre-injection images in the case of apoE− /− mice injected with 
NP-CD163(m). (B) Graph showing the normalized mean value of the abdominal aortic wall for apoE− /− 
and wild type mice injected with either NP-CD163(m) or NP-IgG(m) at 0, 24 and 48 hours. The error bars 
represent the SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 versus apoE + NP-CD163 t = 48h.
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reinforces the fact that the MRI signal is due to the specific labelling of the NP-CD163(m) probe (see 
supplemental Figures S7-S8). The probe is cleared in time in the aorta because its presence was not 
detected via MRI 6 days post-injection. Interestingly, none of the negative controls showed a decrease 
in the wall intensity signal over time. Indeed, apoE− /− mice injected with NP-IgG(m) and wild type 
mice injected with either NP-CD163(m) or NP-IgG(m) did not present any significant changes during 
48 hours after injection with respect to the signal intensity of the aortic wall before the injection. Hence, 
the targeted probe designed by us seems to be able to selectively detect CD163 receptor in the aortic 
wall of mice presenting atherosclerotic lesions. Finally, the in vivo results obtained by MRI were con-
firmed using immunohistochemistry techniques showing the presence of atherosclerotic plaques with 
CD163(+ ) macrophages in the lesions of the mice.
In conclusion, we have proved the versatility of our construction by linking it with different antibod-
ies. The FA-11 and M-96 antibodies linked in our construction were capable to detect CD163 in vitro and 
the M-96 antibody, recognizing the mouse CD163 receptor, linked to our NP was capable of detecting a 
subpopulation of macrophages in atheromatous plaques in vivo.
Methods
Antibodies. Monoclonal anti-human CD163 (AbDserotec, MCA1853), mouse IgG1 negative con-
trol (AbDserotec, MCA928), rabbit polyclonal anti-mouse CD163 (M-96, Santa Cruz, sc-33560), rabbit 
IgG negative control (Santa Cruz, sc-2027), monoclonal Anti-α Smooth Muscle Actin (Sigma-Aldrich, 
A-2547), rat monoclonal anti-mouse CD68 (FA-11, Abcam, ab53444) were used for MRI, western-blot 
and immunohistochemistry detection.
Cell lines and culture medium. The human monocytic cell line THP-1 [American Type Culture 
Collection (ATCC), Rockville, MD] and murine peritoneal macrophages, isolated as previously 
described30, were cultured in RPMI (BioWittaker) supplemented with 10% FBS (BioWittaker), 2 mM 
L-glutamine, 100 U/ml penicillin and 100 μ g/ml streptomicin (Invitrogen). THPs were differentiated to 
macrophages using PMA (10−7 M) for 48 h. After that, THP-1 macrophages cells and murine peritoneal 
macrophages were treated for 24 h with dexamethasone (2.5 × 10−7 M) to induce CD163 expression.
Synthesis of gold-coated iron oxide nanoparticles, functionalization with IgG antibodies and 
characterization. Hexane soluble oleic acid protected iron oxide seeds (Fe3O4@oleic NPs) and gold 
Figure 4. Validation of the plaque presence and molecular biomarkers in apoE−/− mice. Representative 
micrographs of aortic serial sections isolated from apoE− /− NP CD163(m) injected mice. (A) Vascular 
smooth muscle staining by α -actin immunohistochemistry detection, (B) Lipid determination by Oil red 
staining (C) CD68 immunohistochemistry detection and (D) CD163 immunohistochemistry detection. 
(n = 7).
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coated iron oxide nanoparticles (Fe3O4@Au@oleic NPs) herein reported were prepared as described 
before following a modification of a procedure reported by Wang et al.22,31 (Supplemental Figure S1 and 
S2). These nanoparticles were characterized by TEM on a JEOL JEM 2100F microscope before and after 
the gold coating and their composition was determined by XPS analysis on a SPECS Sage HR 100 spec-
trometer, also before and after the coating (Supplemental Figure S3). As previously reported, oleic acid 
protected gold-coated iron oxide nanoparticles (Fe3O4@Au@oleic NPs) underwent a ligand exchange 
step with a 1:1 mixture of carboxylic acid ending ligands and mannose ending ligands to yield water 
soluble Fe3O4@Au nanoparticles (Fe3O4@Au@Man/CO2H NPs). These nanoparticles were characterized 
by TEM, UV-Vis and ICP-OES for the quantification of the gold and iron content. Subsequently, water 
soluble Fe3O4@Au@Man/CO2H NPs were converted into targeted NPs through a peptide coupling with 
amine groups present in protein G (protG, Pierce®Ig Binding protein, Thermo Scientific) and further 
incubation of IgG antibodies with the NP-protG complex, following a two step procedure described by us 
for the same nanoparticles23. Both human and mouse anti-CD163 and their corresponding IgG isotype 
antibodies were conjugated to the NP-protG complex leading to the formation of 4 probes: NP-CD163(h) 
and NP-IgG(h) for human antibodies, and NP-CD163(m) and NP-IgG(m) for mouse antibodies. The 
amount of protG and antibody on the nanoparticles was separately determined by Bradford assay of the 
unbound protG and the antibody recovered in the washings after the peptide coupling and the antibody 
incubation, respectively, as described before23. Additionally, the presence of the antibodies was confirmed 
by SDS-PAGE gels (Supplemental Figure S4).
Specificity studies of nanoparticles. In vitro targeting was pursued to demonstrate the specificity of 
NP-CD163. In order to accomplish that, two cell lines were used, human THP-1 monocyte-macrophage 
cell line and isolated murine macrophages. Macrophages are able to overexpress CD163 under stimula-
tion of dexamethasone as described in Schaer et al.32 and its expression was validated by Western-blot 
or immunofluorescence (Fig. 2A). 106 human cells, expressing or not CD163, were incubated with either 
NP-CD163(h) or NP-IgG(h) (as antibody control) at 4 °C, employing 1.5 μ g of Fe per 106 cells in 300 μ L of 
PBS. After 1 hour the cells were centrifuged to remove the unbound NPs and several washings with PBS 
were performed. The incubated cells were placed in capillary tubes and allowed to form a pellet overnight 
at 4 °C. Those capillary tubes were inserted in agarose gel (2% w/w) to prepare phantoms for MRI. The 
same incubation protocol was applied to murine cells that expressed or not CD163 but using 5× 105 cells 
per incubation. Inhibition studies with both cell lines were performed with increased amounts of free 
antibody (1:1 and 1:10 with respect to the probe), in order to block the NP-CD163 binding to ensure 
that the T2-signal obtained was due to the specificity of the antibody. All incubation and inhibition 
experiments were performed at least 3 times.
Animal model. 8 weeks old B6.129P2-apoEtm1Unc/J transgenic mice (apoE− /− , n = 5–9) as athero-
sclerotic model and healthy wild type mice as control (Wt, n = 3–5) (Jackson Laboratory, Bar Harbor, 
ME) were used for in vivo studies. apoE− /− mice were fed during 8 weeks with high-fat diet (TD.88137 
42% Fat , Harlan Teklan, Madison, Wisconsin) to induce atherosclerosis development. Mice were anes-
thetized for all procedures (isoflurane 2% to 3% v/v, Baxter). The NP-CD163(m) and its negative control 
NP-IgG(m) were injected in a dose of 2 mg Fe/Kg mice intravenously. The institutional subcommittee 
(Provincial Council of Guipuzcoa) on research animal care approved all animal studies, all the studies 
were carried out in accordance with the approved guidelines.
MR Imaging. Measurements were made on an 11.7 Tesla horizontal bore BrukerBiospec 117/16 scan-
ner (Bruker A.G., Ettlingen, Germany). The actively shielded BFG-150/90-S gradient insert (Resonance 
Research Inc. Ballerica, MA, USA) has a 90 mm gradient coils are capable of switching 750 mT/m within 
100 μ s.
Imaging of cells phantoms. T2 relaxation times were calculated from images obtained using a mul-
tiple spin echo sequence with equally spaced 64 echoes ranging from 10 ms to 640 ms and 12000 ms 
repetition time. The in plane resolution was 133 × 133 μ m2 and the slice thickness varied between 300 μ m 
and 500 μ m in the different samples. The slice thickness was varied to avoid partial volume effects from 
the water above the pellet of cells, as the volume of pellet could vary from sample to sample. Each echo 
was acquired 8 times to improve the signal to noise ratio.
Imaging of mice. In vivo images were acquired using a respiratory-triggered flow compensated 
gradient recalled echo sequence. The sequence parameters were the following: TR = ~1 breathing; 
TE = 4 ms; FA = 30°; number of averages = 1; FOV = 2 × 2 cm; in plane resolution = 78 × 78 μ m, slice 
thickness = 0.5 mm. Four adjacent slabs, each containing five slices, of the pararenal abdominal aorta 
were acquired in each experiment with a 1 mm saturation band at 2.5 mm to suppress the downstream 
flow entering the imaged slices. Images of the same mice were acquired before injection and 1, 24 and 
48 hours after injection.
Histopathology and immunohistochemistry. To validate the in vivo MRI imaging, equivalent sec-
tions of the scanned aortas were harvested and embedded in OCT. Serial 4-μ m–thick cryostat sections 
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were stained either with oil red for lipid deposits detection and characterization with the following anti-
bodies: CD163 and CD68 (macrophages), and α -actin (smooth muscle cells). The secondary antibodies 
and ABComplex/HRP were added and sections were stained with 3, 30-diaminobenzidine, counter-
stained with hematoxylin and mounted in DPX. For CD163 detection Tyramide Signal Amplification 
Biotin Kit (PerkinElmer, NEL700A001KT) was needed to improve signal detection. Images were taken 
using a Nikon Eclipse E400 microscope and Nikon ACT-1 software.
Image analysis. MRI and histology images were analyzed using Image J (Image J 1.47v, NIH, USA). 
Signal intensity of the cell pellets placed inside capillary tubes was quantified in each slice for each 
echo time by drawing ROIs (region of interest) on them. Subsequently a monoexponential decay curve 
was fitted to the obtained results to calculate T2 values in each capillary tube using Origin (OriginLab, 
Northampton, MA). The T2 values calculated for each cell pellet were normalized to the T2 value of the 
blank sample (cells without NPs) and compared among them to determine the selectivity of the probes. 
For the in vivo experiments, the aortic vessel wall and the adjacent spinal muscle were manually seg-
mented to determine the signal-to-noise-ratio (SNR) of each. The SNR of the aortic wall was normalized 
to the SNR of the adjacent muscle on each slice and averaged for each animal and time point. Plaque 
size was quantified in two slices of two sections separated from 100 μ m and next to the pararenal aorta.
Statistics. Results are expressed as mean ± SEM. The data among groups were compared by using 
either 1-way ANOVA followed by DMS´s or Games Howell´s post hoc test for multiple comparisons 
depending on Levene’s test for homogeneity of variances. It was considered statistically significant when 
p-value ≤ 0.05.
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